GreenLight™ Laser System for Day-Case Surgery

This symposium took place on 2nd October 2015 at the 33rd World Congress of Endourology and SWL 2015 in London, UK

Chairperson: Ian Jackson1
Speakers: Ian Jackson, Andrea Tubaro,2 Gordon Muir3

1. York Teaching Hospitals NHS Foundation Trust, York, UK
2. Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy
3. King’s College Hospital, London, UK

Disclosure: Ian Jackson has received funding for speaker engagement from Boston Scientific. Andrea Tubaro has served as a consultant for Allergan, AMS/Boston Scientific, Astellas, GSK, and Pfizer, as an investigator for AMS, Astellas, GSK, Pierre Fabre, and Shionogi, and has received a research grant from Astellas. Gordon Muir has received speaker and mentoring fees from Boston Scientific and Neotract.
Acknowledgements: Writing assistance was provided by Dr Juliane Moloney, ApotheCom.
Support: The publication of this article was funded by Boston Scientific. The views and opinions expressed are those of the authors and not necessarily of Boston Scientific.
Citation: EMJ. 2016;1(1):20–23.

Meeting Summary

In light of recent economic challenges, reductions in healthcare spending are vital to sustain the level of care in health services across the world. The British Association of Day Surgery (BADS) recommendations highlight the need to revise post-surgery care and consider short-stay surgery as a viable option in patients undergoing treatment for benign prostatic hyperplasia (BPH).

A comparative study of the GreenLight XPS™ laser system and transurethral resection of the prostate (TURP) reported significant benefits with GreenLight™ Laser Therapy across Europe, and specifically in the UK, in terms of duration of catheterisation, time to stable health, and duration of hospitalisation. In addition, fewer post-surgery complications and morbidity highlight the suitability of GreenLight for daycase treatment in 70% of patients. When based on day-case GreenLight surgery, the direct cost of the GreenLight system is significantly more cost-effective than TURP. Although GreenLight is suitable across the entire patient spectrum, with particular benefits to high-risk patients, a pragmatic approach to assessing the best treatment management for each individual patient is required to allow for adequate care and ultimately patient quality of life.

Click below to view the following videos:
Q&A Session – Impact of the GreenLight TM Laser System for Day-Case Surgery Mr Gordon Muir
Results of the GOLIATH Study Prof Andrea Tubaro
The Importance of Day-Case Surgery Dr Ian Jackson

Download (PDF, 106KB)

Comments are closed.